Physician profile

Ranjitha Veerappan

Anatomic Pathology & Clinical Pathology · Phoenix, AZ

NPI 1578764999

$198.37

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

See the full distribution for Anatomic Pathology & Clinical Pathology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$106.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $106.68 2024 Lux-Dx Insertable Cardiac Monitor
Cardiovascular Systems INC. $35.33 2021
Stemline Therapeutics INC. $22.58 2019
Astrazeneca Pharmaceuticals LP $19.32 2020
Abbott Laboratories $14.46 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ranjitha Veerappan

$198.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/1289107/ranjitha-veerappan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.